Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | TXNRD1 | Q16881 | 5/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5115745 | 0.81 | PDPK1 (0.46) | ALDH1A1CYP2D6KMT2AMEN1LMNA | |
| SCHEMBL11360877 | 0.80 | ALDH1A1 (0.52) | ALDH1A1CYP1A2CYP2D6CYP2C19KMT2A | |
| SCHEMBL14376687 | 0.78 | LTA4H (0.64) | SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL30991285 | 0.77 | TXNRD1 (0.51) | RAB9ATXNRD1MAPT | |
| SCHEMBL27175926 | 0.77 | TXNRD1 (0.51) | RAB9ATXNRD1MAPT | |
| SCHEMBL30991283 | 0.77 | TXNRD1 (0.51) | RAB9ATXNRD1MAPT | |
| SCHEMBL29788583 | 0.77 | KDM4E (0.68) | SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL375580 | 0.77 | KDM4E (0.68) | SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL4106609 | 0.76 | CHEK1 (0.60) | SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL5754304 | 0.75 | TXNRD1 (0.57) | SMN1; SMN2ALDH1A1CYP1A2TXNRD1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214622-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | BROWN ALAN DANIEL | 2008-09-04 | — | — | US | disclosed |
| US-20080214622-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | BROWN ALAN DANIEL | 2008-09-04 | — | — | US | disclosed |
| WO-2006100588-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214622-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | OXTR, PRLHR, KISS1R | SMN1; SMN2 2638/4885ALDH1A1 3792/4885KDM4E 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.